📰 Robert Mancini News
Robert Mancini News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Robert Mancini. Real-time updates on events, politics, business and more.
May 4, 2024
Should Manchester City come out on top again, how much longer can Mikel Arteta maintain the fight against their dominance?
February 9, 2024
Experts provide practical guidelines and key takeaways for health care professionals and policymakers on the implementation of bispecific antibodies in DLBCL (diffuse large B cell lymphoma), emphasizing safety, efficacy, and operational strategies.
February 9, 2024
A panel of experts examines unmet needs in the adoption of bispecific antibody therapy, emphasizing the importance of access and education for diverse stakeholders in oncology care to improve patient outcomes.
February 2, 2024
Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.
February 2, 2024
Experts discuss strategies to reduce treatment-related toxicities in bispecific antibody treatments, emphasizing clarity on dosing, hydration, and safety concerns.
January 31, 2024
Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.
January 31, 2024
Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.
January 31, 2024
Pharmacists discuss emerging therapies, challenges, and pharmacists’ vital role in myelofibrosis patient care, emphasizing disease-modifying agents and care team collaboration.
January 26, 2024
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.
January 26, 2024
Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.